FUSIONCHIP

USPTO USPTO 2003 CANCELLED - SECTION 8

Schützen Sie diese Marke vor Nachahmern!

Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.

Die US-Marke FUSIONCHIP wurde als Wortmarke am 14.05.2003 beim Amerikanischen Patent- und Markenamt angemeldet.
Sie wurde am 01.03.2005 im Markenregister eingetragen. Der aktuelle Status der Marke ist "CANCELLED - SECTION 8".

Markendetails

Markenform Wortmarke
Aktenzeichen 78249506
Registernummer 2928680
Anmeldedatum 14. Mai 2003
Veröffentlichungsdatum 07. Dezember 2004
Eintragungsdatum 01. März 2005

Markeninhaber

2, Boulevard Luce Bat. A
13008 Marseille
FR

Markenvertreter

Waren und Dienstleistungen

5 Diagnostic biological reagents for clinical or medical laboratory use or for determining gene translocations with partner genes which lead to neurological illness, muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Durkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell carcinomas, kidney neoplasms, renal cell carcinomas, papillary carcinomas, follicular adenocarcinomas, endometrial neoplasms, follicular lymphomas, glioblastomas, splenic neoplasms, lung neoplasms, squamous cell carcinomas, giant cell fibroblastoma, Bednar tumors, giant cell carcinomas, skin neoplasms, lipoblastomas, ganglioneuroblastomas, breast neoplasms, hypereosinophilic syndrome, synovial sarcoma; pharmaceutical preparations for treatment of muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Burkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell carcinomas, kidney neoplasms, renal cell carcinomas, papillary carcinomas, follicular adenocarcinomas, endometrial neoplasms, follicular lymphomas, glioblastomas, splenic neoplasms, lungneoplasms, squamous cell carcinomas, giant cell fibroblastoma, Bednar tumors, giant cell carcinomas, skin neoplasms, lipoblastomas, ganglioneuroblastomas, breast neoplasms, hypereosinophilic syndrome, synovial sarcoma
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen

ID: 1378249506